

Nepal Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal			
2. Grant number: 17-NPL-12b-X			
3. Date of Decision Letter: 21 December 2016 (this Decision Letter replaces the Decision letter of 19 November 2015)			
4. Date of the Partnership Framework Agreement: 22 August 2014			
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID			
8. Programme duration¹: 2014 -2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement			
	2014-2016	2017	Total ²
Programme Budget (US\$)	21,525,000 ³	4,936,500	26,461,500
10. Vaccine introduction grant (in US\$): Not applicable.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2014-2016	2017	
Number of Pneumococcal vaccines doses		1,461,000	
Annual Amounts (US\$)	21,525,000 ⁵	4,936,500	
12. Procurement agency: UNICEF The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 17-NPL-12b-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>							
Type of supplies to be purchased with Country funds in each year	2017						
Number of vaccine doses	103,800						
Value of vaccine doses (US\$)	316,427						
Total co-financing payments (US\$) (including freight)	319,500						
<p>15. Operational support for campaigns: Not applicable</p>							
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May2017</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May2017	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May2017						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat						
<p>17. Financial clarifications: Not applicable</p>							
<p>18. Other conditions: Country is reminded of its obligations under the Partnership Framework Agreement in respect of insurance and is requested to provide information to Gavi Secretariat on the steps it has taken in this regard.</p>							

Signed by,


 Baty Greene
 Managing Director
 Finance & Operations

for:

On behalf of Gavi GAVI Alliance
 Hind Khatib-Othman
 Managing Director, Country Programmes
 21 December 2016

Nepal Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal			
2. Grant number: 17-NPL-04c-X			
3. Date of Decision Letter: 21 December 2016 (this Decision Letter replaces the Decision letter of 19 November 2015)			
4. Date of the Partnership Framework Agreement: 22 August 2014			
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme duration⁶: 2009 -2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2009-2016	2017	Total ⁷
Programme Budget (US\$)	36,646,206 ⁸	1,573,000	38,219,206
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁹			
Type of supplies to be purchased with Gavi funds in each year	2012-2016	2017	
Number of Pentavalent vaccines doses		1,313,500	
Annual Amounts (US\$)	36,646,206 ¹⁰	1,573,000	
12. Procurement agency: UNICEF The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			

⁶ This is the entire duration of the Programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 17-NPL-04c-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccine doses	264,000
Value of vaccine doses (US\$)	309,070
Total co-financing payments (US\$) (including freight)	315,500

15. Operational support for campaigns: Not applicable

16. Additional reporting requirements:

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: The country is reminded of its obligations under the PFA in respect of insurance and is requested to provide information to Gavi on the steps it has taken in this regard.

Signed by,


 Barry Greene
 Managing Director
 Finance & Operations
 The GAVI Alliance

fw: **On behalf of Gavi**
 Hind Khatib-Othman
 Managing Director, Country Programmes
 21 December 2016

Nepal Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal			
2. Grant number: 17-NPL-09a-X			
3. Date of Decision Letter: 21 December 2016 (this Decision Letter replaces the Decision letter of 19 November 2015)			
4. Date of the Partnership Framework Agreement: 22 August 2014			
5. Programme title: New vaccine support (NVS), Measles Second Dose (MSD) as Measles-Rubella			
6. Vaccine type: Measles-Rubella			
7. Requested product presentation and formulation of vaccine: Measles Rubella, 10 dose(s) per vial, LYOPHILISED			
8. Programme duration¹: 2015 -2017			
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)			
	2015-2016	2017	Total ²
Programme Budget (US\$)	US\$ 739,500 ³	US\$125,500	US\$ 865,000
10. Vaccine introduction grant (in US\$): Not applicable			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴			
Type of supplies to be purchased with Gavi funds in each year	2015-2016	2017	
Number of Measles-Rubella vaccines doses		434,400	
Annual Amounts (US\$)	739,500 ⁵	US\$125,500	
12. Procurement agency: UNICEF The Country shall release its co-financing payments each year to UNICEF.			
13. Self-procurement: Not applicable			
14. Co-financing obligations: Not applicable			

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

18/12

15. Operational support for campaigns: Not applicable	
16. Additional reporting requirements:	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable	
18. Other conditions:	
Country has presented an official request to Gavi to switch from measles vaccine to measles- rubella vaccine for the routine measles second dose with country funding for the equivalent cost of the rubella component. As such, country will make the required payments to UNICEF SD as indicated in the table below.	
	2017
Number of doses of vaccines for Measles Second Dose approved by Gavi.	434,400
Amount for vaccines approved by Gavi in US\$ (excluding freight and insurance).	US\$121,632
Number of doses of Measles-Rubella vaccine that can be purchased with Gavi support.	199,397
Number of doses of Measles-Rubella vaccine to be funded by country.	235,003
Amount for Measles-Rubella vaccines to be funded by country (excluding freight and insurance).	US\$ 143,352
<p>In the case of procurement through UNICEF, Gavi-funded vaccines will be purchased only after receipt of full payment of the respective amounts due from Country for the number of doses as indicated in this Decision Letter. Country is required to submit a request for a Cost Estimate to UNICEF, with a clear reference to the approval code and approval year. Country will inform Gavi Secretariat when payment of the respective amount due under this Cost Estimate has been fully made to UNICEF.</p> <p>In the event that country wishes to revert to measles vaccine, country should inform UNICEF and Gavi immediately in order to agree on an appropriate arrangement.</p> <p>Country is also reminded of its obligations under the Partnership Framework Agreement in respect of insurance and is requested to provide information to Gavi Secretariat on the steps it has taken in this regard.</p>	

Signed by,



Barry Greene
 Managing Director
 Finance & Operations
 The GAVI Alliance



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 21 December 2016

Nepal Support for Injection Safety Devices

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal		
2. Grant number: 17-NPL-32a-X		
3. Date of Decision Letter: 21 December 2016		
4. Date of the Partnership Framework Agreement: 22 August 2014		
5. Programme title: Injection Safety Devices ¹		
6. Programme duration²: 2017		
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)		
	2017	Total³
Programme Budget (US\$)	162,000	162,000
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴		
TOTAL Injection Safety Devices to be purchased with Gavi funds in each year	2017	
Number of AD syringes	3,169,700	
Number of re-constitution syringes	47,800	
Number of safety boxes	35,450	
Annual Amounts for Injection Safety Devices for all Gavi vaccines (US\$)	162,000	
Injection Safety Devices to be purchased with Gavi funds in each year, by type of support		
New Vaccine Support (NVS), Pneumococcal (PCV10), 2 doses per vial, LIQUID, Routine	2017	
Number of AD syringes	1,535,300	
Number of re-constitution syringes		
Number of safety boxes	16,900	
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	77,500	

¹ This does not include vaccines.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁴ This is the amount that Gavi has approved.

New Vaccine Support (NVS), DTP-HepB-Hib, 10 doses per vial, LIQUID, Routine	2017
Number of AD syringes	1,236,700
Number of safety boxes	13,625
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	62,500
New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 doses per vial, LIQUID, Routine	2017
Number of AD syringes	317,300
Number of safety boxes	3,500
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	16,000
New Vaccine Support (NVS), Measles Rubella, 10 dose(s) per vial, LYOPHILISED, MSD	2017
Number of AD syringes	80,400
Number of re-constitution syringes	47,800
Number of safety boxes	1,425
Annual Amounts for Injection Safety Devices for Vaccine (US\$)	6,000
9. Procurement agency: UNICEF The Country shall release its co-financing payments each year to UNICEF.	
10. Self-procurement: Not applicable	
11. Co-financing obligations: Not applicable	

Signed by,


Barry Greene
Managing Director
Finance & Operations
The GAVI Alliance

hw

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
21 December 2016